Axsome Therapeutics Announces Expedited Development of AXS-12 for the Treatment of Narcolepsy Based on FDA Breakthrough Therapy Meeting
September 21, 2020 07:00 ET
|
Axsome Therapeutics, Inc.
Single Phase 3 trial to be conducted to support an NDA filing of AXS-12 in the treatment of narcolepsy; trial initiation anticipated 1Q 2021 Extensive patient safety database, previously obtained...
Axsome Therapeutics to Present Data from the CONCERT Phase 2 Trial of AXS-12 in Narcolepsy at the SLEEP 2020 Annual Meeting
August 28, 2020 07:00 ET
|
Axsome Therapeutics, Inc.
NEW YORK, Aug. 28, 2020 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS)...
Axsome Therapeutics Receives FDA Breakthrough Therapy Designation for AXS-12 for the Treatment of Narcolepsy
August 05, 2020 07:00 ET
|
Axsome Therapeutics, Inc.
Designation offers potential for expedited development and review FDA Orphan Drug Designation previously granted to Axsome for AXS-12 in narcolepsy Third FDA Breakthrough Therapy designation...
Axsome Therapeutics to Report Second Quarter 2020 Financial Results on August 10, 2020
July 30, 2020 07:00 ET
|
Axsome Therapeutics, Inc.
Axsome to host conference call and webcast on Monday, August 10, 2020 at 8:00 AM Eastern Time NEW YORK, July 30, 2020 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a...
Axsome Therapeutics Reports First Quarter 2020 Financial Results and Provides Business Update
May 08, 2020 07:00 ET
|
Axsome Therapeutics, Inc.
Clinical successes highlight Axsome’s accelerated evolution into a leading CNS company Positive pivotal Phase 2/3 results for AXS-05 in Alzheimer’s disease agitation further deepen innovative...
Axsome Therapeutics Enters into Exclusive License Agreement with Pfizer Inc. for Pfizer’s Reboxetine Clinical and Nonclinical Data and for New Phase 3 Esreboxetine Product Candidate
January 13, 2020 06:00 ET
|
Axsome Therapeutics, Inc.
Agreement accelerates ongoing clinical development of AXS-12 (reboxetine) in narcolepsy Expands Axsome’s pipeline with new Phase 3-stage esreboxetine product candidate for fibromyalgia ...
Axsome Therapeutics Announces AXS-12 Achieves Primary Endpoint in CONCERT Phase 2 Trial in Narcolepsy
December 03, 2019 06:00 ET
|
Axsome Therapeutics, Inc.
Demonstrated statistically significant reduction in cataplexy attacks compared to placebo (p<0.001 on primary endpoint) Reduced excessive daytime sleepiness compared to placebo (p=0.003 on ESS;...
Axsome Therapeutics Reports Third Quarter 2019 Financial Results and Provides Business Update
November 07, 2019 07:00 ET
|
Axsome Therapeutics, Inc.
GEMINI Phase 3 placebo-controlled trial of AXS-05 in MDD completed enrollment and on track for readout of topline results by year-end 2019 STRIDE-1 Phase 3 trial of AXS-05 in TRD to conclude patient...
Sleep Tech Devices Market value to cross $27 billion by 2025: Global Market Insights, Inc.
November 05, 2019 05:00 ET
|
Global Market Insights, Inc
Selbyville, Delaware, Nov. 05, 2019 (GLOBE NEWSWIRE) -- Global Sleep Tech Devices Market is projected to surpass USD 27 billion by 2025, according to a new research report by Global Market...
Axsome Therapeutics Completes Patient Enrollment in the CONCERT Phase 2 Trial of AXS-12 in Narcolepsy
October 21, 2019 07:00 ET
|
Axsome Therapeutics, Inc.
NEW YORK, Oct. 21, 2019 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous...